# OnCo record alk (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/alk/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "alk" ;
  schema:name "ALK"@en ;
  schema:description "ALK is a gene fusion driver in about 4 to 5% of non-small-cell lung cancers that responds to a succession of ALK inhibitor pills. Lorlatinib kept about 60% of patients progression-free at five years, alectinib is approved after surgery, and neladalkib targets compound resistance mutations."@en ;
  schema:url <https://onco.cc/targets/alk/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Anaplastic_lymphoma_kinase>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171094>, <https://www.uniprot.org/uniprotkb/Q9UM73/entry>, <https://www.ncbi.nlm.nih.gov/gene/238> ;
  owl:sameAs <http://www.wikidata.org/entity/Q17824987> ;
  schema:citation <https://en.wikipedia.org/wiki/Anaplastic_lymphoma_kinase> ;
  onco:tag "driver", "kinase" ;
  schema:alternateName "ALK" ;
  onco:targetClass "kinase" ;
  onco:firstDescribed "1994"^^xsd:gYear ;
  onco:related <https://onco.cc/biomarkers/alk-fusion/>, <https://onco.cc/biomarkers/alk-resistance-mutation/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/neuroblastoma/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/colorectal/> ;
  onco:drugs <https://onco.cc/drugs/ceritinib/>, <https://onco.cc/drugs/brigatinib/>, <https://onco.cc/drugs/ensartinib/>, <https://onco.cc/drugs/guardant360-cdx/>, <https://onco.cc/drugs/tri-611/> ;
  onco:companies <https://onco.cc/companies/imagene-ai/>, <https://onco.cc/companies/inivata/>, <https://onco.cc/companies/lucence/>, <https://onco.cc/companies/triana-biomedicines/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/nsclc-signalling/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/resistance/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-singhi-alk-rearrangements-pancreatic-jnccn-2017/>, <https://onco.cc/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/>, <https://onco.cc/key-papers/paper-soda-eml4-alk-fusion-nature-2007/>, <https://onco.cc/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/> .